A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions

mAbs

Volumn 6, Issue 3, 2014, Pages 622-627

  Lee, Chingwei V ^a   Koenig, Patrick ^a   Fuh, Germaine ^a  

^a GENENTECH INC   (United States)

Author keywords

Bispecific antibody; Dual action fab; Dual specific antibody; IL5; Phage display

Indexed keywords

ALANINE; IMMUNOGLOBULIN G; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 5; TRASTUZUMAB; BISPECIFIC ANTIBODY; COMPLEMENTARITY DETERMINING REGION; IL4 PROTEIN, HUMAN; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 4; MONOCLONAL ANTIBODY; PEPTIDE LIBRARY;

ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BIOLOGICAL ACTIVITY; COMPLEMENTARITY DETERMINING REGION; DISSOCIATION CONSTANT; GENE MUTATION; HEAVY CHAIN; HUMAN; LIGHT CHAIN; PHAGE DISPLAY; ANIMAL; ANTIBODY COMBINING SITE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; IMMUNOLOGY; MOUSE; MUTAGENESIS; PEPTIDE LIBRARY; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; BINDING SITES, ANTIBODY; COMPLEMENTARITY DETERMINING REGIONS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; INTERLEUKIN-4; MICE; MODELS, MOLECULAR; MUTAGENESIS; PEPTIDE LIBRARY; PROTEIN ENGINEERING;

EID: 84899748992     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.28483     Document Type: Article

References (26)

1. Dhimolea E, Reichert JM. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA. MAbs 2012; 4:4-13; PMID:22327426; http://dx.doi.org/10. 4161/mabs.4.1.18821
2. Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012; 4:182-97; PMID:22453100; http://dx.doi.org/10.4161/mabs.4.2.19000
3. Eigenbrot C, Fuh G. Two-in-One antibodies with dual action Fabs. Curr Opin Chem Biol 2013; 17:400-5; PMID:23683347; http://dx.doi.org/10.1016/j.cbpa. 2013.04.015
4. Koenig P, Fuh G. Two-in-One antibodies. In: Kontermann R, ed. Bispecific antibodies: Springer, 2011:187-98.
5. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323:1610-4; PMID:19299620; http://dx.doi.org/10.1126/science.1165480
6. Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS One 2011; 6:e17887; PMID:21526167; http://dx.doi.org/10.1371/journal.pone.0017887
7. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20:472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003
8. Colby DW, Garg P, Holden T, Chao G, Webster JM, Messer A, Ingram VM, Wittrup KD. Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J Mol Biol 2004; 342:901-12; PMID:15342245; http://dx.doi.org/10.1016/j.jmb.2004.07.054
9. rd, Jackman J, Chiang N, Nakamura G, Dillon M, Liu H, Molina P, Elliott JM, Shatz W, et al. Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines. J Biol Chem 2013; 288:26583-93; PMID:23880771; http://dx.doi.org/10.1074/jbc.M113.480483
10. Lee CV, Sidhu SS, Fuh G. Bivalent antibody phage display mimics natural immunoglobulin. J Immunol Methods 2004; 284:119-32; PMID:14736422; http://dx.doi.org/10.1016/j.jim.2003.11.001
11. Sidhu SS, Li B, Chen Y, Fellouse FA, Eigenbrot C, Fuh G. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J Mol Biol 2004; 338:299-310; PMID:15066433; http://dx.doi.org/10.1016/j.jmb. 2004.02.050
12. Lee CV, Liang WC, Dennis MS, Eigenbrot C, Sidhu SS, Fuh G. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol 2004; 340:1073-93; PMID:15236968; http://dx.doi.org/10.1016/j.jmb.2004.05.051
13. LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, Keegan AD, Garcia KC. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 2008; 132:259-72; PMID:18243101; http://dx.doi.org/10.1016/j.cell.2007.12.030
14. Milburn MV, Hassell AM, Lambert MH, Jordan SR, Proudfoot AE, Graber P, Wells TN. A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature 1993; 363:172-6; PMID:8483502; http://dx.doi.org/10.1038/363172a0
15. Patino E, Kotzsch A, Saremba S, Nickel J, Schmitz W, Sebald W, Mueller TD. Structure analysis of the IL-5 ligand-receptor complex reveals a wrench-like architecture for IL-5Rα. Structure 2011; 19:1864-75; PMID:22153509; http://dx.doi.org/10.1016/j.str.2011.08.015
16. Finkelman FD, Hogan SP, Hershey GK, Rothenberg ME, Wills-Karp M. Importance of cytokines in murine allergic airway disease and human asthma. J Immunol 2010; 184:1663-74; PMID:20130218; http://dx.doi.org/10.4049/jimmunol. 0902185
17. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-84; PMID:19264686; http://dx.doi.org/10.1056/NEJMoa0808991
18. Hötzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs 2012; 4:753-60; PMID:23778268; http://dx.doi.org/10.4161/mabs.22189
19. Bostrom J, Lee CV, Haber L, Fuh G. Improving antibody binding affinity and specificity for therapeutic development. Methods Mol Biol 2009; 525:353-76, xiii; PMID:19252851; http://dx.doi.org/10.1007/978-1-59745-554-1-19
20. Lee CV, Hymowitz SG, Wallweber HJ, Gordon NC, Billeci KL, Tsai SP, Compaan DM, Yin J, Gong Q, Kelley RF, et al. Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood 2006; 108:3103-11; PMID:16840730; http://dx.doi.org/10.1182/blood-2006-03-011031
21. Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 1992; 224:487-99; PMID:1560463; http://dx.doi.org/10.1016/0022-2836(92)91010-M
22. Kelley RF, O'Connell MP. Thermodynamic analysis of an antibody functional epitope. Biochemistry 1993; 32:6828-35; PMID:7687461; http://dx.doi.org/10. 1021/bi00078a005
23. Cunningham BC, Jhurani P, Ng P, Wells JA. Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis. Science 1989; 243:1330-6; PMID:2466339; http://dx.doi.org/10.1126/science.2466339
24. Vajdos FF, Adams CW, Breece TN, Presta LG, de Vos AM, Sidhu SS. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol 2002; 320:415-28; PMID:12079396; http://dx.doi.org/10.1016/S0022-2836(02)00264-4
25. Kunkel TA, Roberts JD, Zakour RA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol 1987; 154:367-82; PMID:3323813; http://dx.doi.org/10.1016/0076-6879(87)54085-X
26. Koenig P, Fuh G. Selection and screening using antibody phage display libraries. Methods Mol Biol 2014; 1131:133-49; PMID:24515464; http://dx.doi.org/10.1007/978-1-62703-992-5-9